GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ind-Swift Laboratories Ltd

Ind-Swift Labs Q2 FY27: Operating Income Up 50.15% to ₹234.89 crore

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 30 Oct 2026, 05:51 PM IST  ·  BSE ID: 0be97587-b25e-4401-813e-d0106f4918ca
View Original BSE Filing (PDF)
💡
In Simple Terms
Ind-Swift Laboratories significantly increased its Q2 revenue and profits, primarily by focusing on ready-to-use medicines.
🤖 AI Summary
  • Ind-Swift Laboratories' Q2 FY27 operating income rose 50.15% to ₹234.89 crore.
  • Operating EBITDA for Q2 FY27 surged 4.95x to ₹42.33 crore, with margin at 18.02%.
  • PAT increased 3.54x to ₹31.03 crore, with PAT margin at 13.21% for Q2 FY27.
  • Half-year FY27 operating income grew 35.79% to ₹420.97 crore and PAT rose 3.29x to ₹55.47 crore.
  • Raw material expense decreased to 45.15% of revenue in Q2 FY27 from 49.38% in Q2 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Operating Income (Q2 FY27)
₹234.89 crore
50.15
Op. EBITDA (Q2 FY27)
₹42.33 crore
4.95x
Op. EBITDA (%) (Q2 FY27)
18.02
1256.01 BPS
PAT (Q2 FY27)
₹31.03 crore
3.54x
PAT Margin (%) (Q2 FY27)
13.21
761.18 BPS
Operating Income (H1 FY27)
₹420.97 crore
35.79
Op. EBITDA (H1 FY27)
₹75.65 crore
4.45x
PAT (H1 FY27)
₹55.47 crore
3.29x
Finance Cost (Q2 FY27)
₹1.33 crore
-33.83
Raw Material Expense (% of Revenue) (Q2 FY27)
45.15%
🏢 How This Affects the Company
📈
Business Impact
The company's transition from API to Finished Dosage Formulations (FDF) manufacturing contributed to revenue growth and improved business mix, impacting market positioning.
💰
Financial Impact
Operating EBITDA surged 4.95x to ₹42.33 crore, and PAT increased 3.54x to ₹31.03 crore, significantly improving profitability and margins. Finance costs declined 33.83% to ₹1.33 crore.
⚙️
Operational Impact
Scale-up of FDF operations and CDMO partnerships contributed to the performance, indicating enhanced operational efficiency and capacity utilization.
⚠️
Risk Impact
The shift to FDF and a net-debt-free balance sheet could potentially reduce financial leverage risks for the company.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company reported a significant increase in profitability and margins for Q2 and H1 FY27, with operating income at ₹234.89 crore and PAT at ₹31.03 crore for the quarter.
🔍
Management Signal
Management commentary emphasizes a successful strategic transition to Finished Dosage Formulations, focus on profitable growth, and a commitment to scaling operations with a net-debt-free balance sheet.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — check if revenue and profitability growth continue.
Updates on CDMO partnerships — assess further contributions to topline.
Information on further operational scale-up initiatives to sustain growth.
LOW RISK The filing reports strong financial performance with improved margins and a net-debt-free balance sheet.
💡 Investor Takeaway
Ind-Swift Laboratories reported Q2 FY27 operating income of ₹234.89 crore, up 50.15% YoY. Operating EBITDA increased 4.95x to ₹42.33 crore, with PAT rising 3.54x to ₹31.03 crore, driven by the FDF business transition and operational scale-up.
⚖️ Strengths & Concerns

✅ Positives

  • Operating income for Q2 FY27 grew 50.15% to ₹234.89 crore, indicating strong topline expansion from core operations.
  • Operating EBITDA surged 4.95x to ₹42.33 crore, expanding margin by 1256.01 BPS to 18.02% in Q2 FY27.
📅 Company Track Record
Previous filings for Ind-Swift Laboratories reported Q2 FY27 standalone net profit rising 254.33% to Rs. 3102.82 Lakhs (which is Rs. 31.0282 crore), consistent with the 3.54x PAT increase to ₹31.03 crore in this filing.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Ind-Swift Laboratories' operating income for Q2 FY27?
Ind-Swift Laboratories reported an operating income of ₹234.89 crore for Q2 FY27, marking a 50.15% increase compared to Q2 FY26.
How much did Ind-Swift Laboratories' PAT increase in Q2 FY27?
The Company's PAT for Q2 FY27 increased 3.54x to ₹31.03 crore, up from ₹8.76 crore in Q2 FY26.
What was Ind-Swift Laboratories' Operating EBITDA for the first half of FY27?
For H1 FY27, Ind-Swift Laboratories' Operating EBITDA rose 4.45x to ₹75.65 crore, with a margin of 17.97%.
How did raw material expense change for Ind-Swift Laboratories in Q2 FY27?
Raw material expense fell to 45.15% of revenue in Q2 FY27, down from 49.38% in Q2 FY26.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.